Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Department of General Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Clin Chim Acta. 2018 Sep;484:91-98. doi: 10.1016/j.cca.2018.05.011. Epub 2018 May 17.
Studies have reported that Zinc finger E-box binding homeobox 1 antisense 1 (ZEB1-AS1) is overexpressed in many malignant tumors. However, the sample size in those studies was limited, so the clinicopathological and prognostic value of ZEB1-AS1 in solid tumors remains undetermined, Accordingly, the aim of this meta-analysis was to evaluate the relationship between the expression of lncRNA ZEB1-AS1 and clinicopathological characteristics and prognosis in patients with solid tumors.
Pooled odds ratios (ORs) and hazard ratios (HRs) were estimated with 95% confidence interval (CI) to assess the relation between ZEB1-AS1 and the clinicopathological characteristics and prognosis of patients with cancer.
A total of 10 studies, comprising 861 patients, were included in this meta-analysis. The pooled results suggested that high ZEB1-AS1 expression was related to low differentiation (low vs. high + moderate: OR = 2.99, 95% CI = [2.03, 4.39]), increased lymph node metastasis (YES vs. NO: OR = 4.62, 95% CI = [2.90, 7.37]) and advanced TNM stage (I + II vs. III + IV: OR = 0.41, 95% CI = [0.23, 0.75]), but not to gender and tumor size. Moreover, high ZEB1-AS1 expression was associated with poor overall survival (OS; HR = 1.86, 95% CI = [1.57, 2.14]) and disease-free survival (DFS; HR = 2.03, 95% CI = [1.28, 2.77]). Thus, ZEB1-AS1 could be an independent predictive factor for OS (HR = 2.07, 95% CI = [1.57, 2.56]) in patients with cancers.
High expression of ZEB1-AS1 was associated with advanced clinicopathological characteristics, and ZEB1-AS1overexpression may be a potential prognostic biomarker in human cancer. However, more studies involving various tumor types and large sample size are needed.
研究表明，锌指 E 盒结合同源盒 1 反义 1（ZEB1-AS1）在许多恶性肿瘤中过度表达。然而，这些研究的样本量有限，因此 ZEB1-AS1 在实体瘤中的临床病理和预后价值仍不确定。因此，本荟萃分析的目的是评估 lncRNA ZEB1-AS1 的表达与实体瘤患者的临床病理特征和预后之间的关系。
使用 95%置信区间（CI）计算合并优势比（OR）和风险比（HR）来评估 ZEB1-AS1 与癌症患者临床病理特征和预后的关系。
共有 10 项研究，包括 861 名患者，纳入本荟萃分析。汇总结果表明，ZEB1-AS1 高表达与低分化（低 vs. 中+高：OR=2.99，95%CI=[2.03,4.39]）、淋巴结转移增加（是 vs. 否：OR=4.62，95%CI=[2.90,7.37]）和较晚的 TNM 分期（I+II vs. III+IV：OR=0.41，95%CI=[0.23,0.75]）相关，但与性别和肿瘤大小无关。此外，ZEB1-AS1 高表达与总生存期（OS；HR=1.86，95%CI=[1.57,2.14]）和无病生存期（DFS；HR=2.03，95%CI=[1.28,2.77]）不良相关。因此，ZEB1-AS1 可能是癌症患者 OS（HR=2.07，95%CI=[1.57,2.56]）的独立预测因子。
ZEB1-AS1 高表达与较先进的临床病理特征相关，ZEB1-AS1 过表达可能是人类癌症的潜在预后生物标志物。然而，需要更多涉及多种肿瘤类型和大样本量的研究。
